UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Stem cell based anti-NASH drug testing: a pragmatic approach for a complex disease

Non-alcoholic fatty liver disease (NAFLD) ranges from simple hepatic steatosis to severe, life-threatening non-alcoholic steatohepatitis (NASH). Steatosis is mostly asymptomatic and does not cause health complications.

Read More

Empowering patients: creating a healthcare data Blockchain network

Alongside my primary role as a Project Manager, I have since 2016 been the Roche lead for the IMI industry collaboration called EHR4CR. EHR4CR is a group of roughly 10 pharma companies, universities, and SMEs working together to leverage the great wealth of information from hospitals in order to support our clinical trials and promote innovative research. It was a 7-year $16 million project.

Read More

The Genetics of progressive NAFLD

Over the last decade, the understanding of genetic factors impacting progressive liver disease has greatly increased. At the 2nd Global NASH Congress, Associate Professor at the University of Milan, Luca Valenti’s research showed the I148M variant of PNPLA3 to be the main common genetic determinant of NAFLD, and how this discovery can be translated into therapeutic approaches.

Read More

PathLAKE: Benefitting Pathologists with exemplary projects

David Snead is Consultant Histopathologist and Clinical lead for Coventry and Warwickshire Pathology Services (CWPS), a network of labs hosted by University Hospitals of Coventry and Warwickshire NHS Trust. As head of the UHCW Digital Pathology Centre of Excellence, he is now heavily involved in the Pathology image data Lake for Analytics, Knowledge, and Education (PathLAKE).

Read More

Predicting future threats by approaching CyberSecurity from all angles

Merck, Sharp & Dohme operates a hub model with IT hubs in the US, Czech Republic, and Singapore.

All operations and important functions of IT are distributed within those three hubs. It ensures not only that we follow the standard model but also ensures the regional presence and cooperation with the sites in any region.

Read More

Using pathogen genome-informed strategies to understand the molecular mechanism plant disease

A key feature of our Congresses is the opportunity given to early career researchers to present their work.

At the upcoming 7th Plant Genomics & Gene Editing Congress: EuropeEgem Ozbudak will be one of four early career researchers to be given a 15-minute platform to present their work and receive a free registration pass for both days of the conference.

He will be discussing his research project on Colletotrichum acutatum, the causative agent of anthracnose crown and fruit rot, recognized as the second most important pathogen of strawberries on the globe due to its economic impacts.

Read More

Immuno-oncology: A Saving Grace in Cancer Treatment

Technology is constantly changing the healthcare industry. Scientists and physicians are hard at work doing everything they can to enhance treatment options for patients battling many different types of diseases and cancers. Immuno-oncology (I-O) is a subarea of immunotherapy that is uncovering new ways that cancer can be treated. This type of treatment allows patients to participate in less invasive and taxing procedures all while finding newer treatment options on a more niche or case by case level. Immunotherapy treatments and supporting procedures are making their way into everyday cancer care to change the playing field for the better.

Read More

Discovering the dynamics of prophage induction in the gut ecosystem

The human gut is a complex ecosystem dominated by bacteria and their viruses, i.e. phages. Approximately half of the viruses that reside in our intestine are derived from lysogens, bacteria that contain normally dormant viruses – prophages — in their genome.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive